10/25/22: Aegle Therapeutics announces that Hema Gopalan has joined as VP Finance.
10/10/22: Aegle Therapeutics presents at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.
10/05/22: Aegle Therapeutics presents at the 4th Annual Extracellular Vesicle-based Therapeutic Development Summit in Boston, MA.
12/02/2020: Aegle Therapeutics’ big mission: Tackling a horrific pediatric disorder [Click]
10/08/2020: Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense's ("DoD") Congressionally Directed Medical Research Programs ("CDMRP") for Development of AGLE-102 [Click]
10/06/2020: Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa [Click]
10/01/2020: FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa [Click]
9/29/2020: Aegle Therapeutics Completes $6.5M Series A Financing [Click]
1/7/2020: Aegle Therapeutics welcomes Elona Baum, Lonnie Moulder and David Schimel to its Board of Directors [Click]
1/7/2020: Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa [Click]
8/9/2019: Aegle Wins Debra’s Partners in Progress Award, Plans to Soon Open Clinical Trial in DEB Patients [Click]
5/20/2019: Aegle Therapeutics Corp. Receives IND Clearance from FDA for Its MSC-Derived Extracellular Vesicle Therapy for Dystrophic Epidermolysis Bullosa [Click]
5/15/2018: Aegle Therapeutics Corporation today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle expects to initiate a Phase 1/2a clinical trial of AGLE-102 for the treatment of severe burn patients in late 2018. [Click]
4/10/2018: Aegle Therapeutics researchers publish Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts in Biochimie, April 10, 2108. [Click]
12/19/2017: Aegle announces the appointment of Dr. Robert Ryan, CEO of Innova Therapeutics, to its board of directors. [Click]